Cash runway reaches 2029 as SOLARA Phase III enrollment begins
COAG Hemab Therapeutics Holdings, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
COAG
—
—
What changed
Recent filings, trades and moves- Nov 10 8-K: Earnings results
- Nov 10 Quarterly report (10-Q) filed
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $2.0B
- List Date
- 2026-05-01
- CIK
- 0002114044
- Last Earnings
- Aug 11
- Headquarters
- Cambridge, MA
- Homepage
- https://www.hemab.com
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic thera…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -- | -- |
| Mar | -- | -- |
| Apr | -- | -- |
| May | -16.18% | -16.18% |
| Jun | 35.39% | 35.39% |
| Jul | 44.05% | 44.05% |
| Aug | 1.62% | 1.62% |
| Sep | -29.94% | -29.94% |
| Oct | 33.45% | 33.45% |
| Nov | -5.54%* | -5.54% |
| Dec | -- | -- |
| Total | 46.71% | 46.71% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $38.73
SMA 50: $37.26
SMA 200: —
Current: $40.92
EMA 12: $41.25
EMA 26: $39.16
MACD: 2.0939 | Signal: 0.3156
BULLISH
ADX (14): 34.66
TREND
+DI: 24.36
−DI: 22.01
Momentum Oscillators
RSI (14): 53.66
NEUTRAL
Stoch %K: 42.52
Stoch %D: 62.63
Williams %R: -56.95
Volume & Volatility
BB Upper: $48.55
BB Lower: $28.92
NEUTRAL
OBV: 8,014,938
Vol SMA 20: 482,549
Vol ROC: -98.38%
ATR: $3.35
True Range: $2.15
HV 20: 94.7%
HV 30: 85.4%
HV 60: 76.9%
Data Summary
Data Points: 134
Last Updated:
Date Range: 2026-05-01T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before COAG’s Nov 10 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: COAG
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a neutral market with no clear direction.
- Recent news headlines have been positive, but the company's beta is high, indicating increased volatility.
- Risk management considerations are crucial due to the stock's sensitivity to market movements.
Investment Thesis: COAG's recent clinical data and product developments in von Willebrand disease and heavy menstrual bleeding may drive future growth. However, the high-beta profile and volatility indicate a higher risk profile.
Recent News Sentiment Impact: The positive sentiment from recent headlines (Hemab Therapeutics' presentations at ISTH 2026 Congress and closing of upsized initial public offering) has contributed to the stock's moderate price movement.
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL
- Medium-term: NEUTRAL
- Long-term: BEARISH (based on SMA 200 not available)
Support/Resistance Levels: $44.95 (lower Bollinger Band), $50.24 (SMA 20 and EMA 12)
Momentum Signals:
- RSI interpretation: NEUTRAL (52.35)
- MACD signal: BULLISH (crossed above the signal line)
- Bollinger Bands position: NEUTRAL (price near middle band)
Volume Analysis: Volume trends are mixed, but institutional interest is moderate with an OBV of 9791974.76.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from Hemab Therapeutics' presentations and initial public offering closing have contributed to the stock's price movement.
Sentiment Assessment: POSITIVE (aggregate sentiment)
Catalyst Identification: Upcoming earnings announcements and product developments in von Willebrand disease and heavy menstrual bleeding may drive future growth.
Market Narrative: The positive news headlines align with the technical signals, suggesting a moderate risk profile.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock (beta: 1.43 vs SPY)
Volatility Regime: Current volatility is higher than historical levels (HV20 62.7%, HV30 72.9%, HV60 88.9%)
Options Market Signals: No options data available.
Downside Protection: Support levels are at $44.95, and risk management considerations are crucial due to the high-beta profile.
Market Context & Positioning
Sector Performance: COAG is a biotech stock, which has been performing relatively well compared to other sectors.
Institutional Activity: Moderate institutional interest with an OBV of 9791974.76.
Correlation Analysis: The stock moves moderately correlated (R-squared: 0.19) with the broader market.
Relative Valuation: COAG is positioned within a trading range, but its beta and volatility suggest a higher risk profile.
Key Levels & Action Items
Critical Price Levels: $44.95 (lower Bollinger Band), $50.24 (SMA 20 and EMA 12)
Breakout/Breakdown Levels: No specific levels available due to the neutral market trend.
Time-Sensitive Catalysts: Upcoming earnings announcements and product developments in von Willebrand disease and heavy menstrual bleeding.
Risk Management: Stop-loss levels should be set near $44.95, and position sizing considerations are crucial due to the high-beta profile.
Generated
News
All COAG news →
COAG Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.7382
Alpha: 57.70%
Correlation: 0.1167
R-Squared: 1.4%
Stock Volatility: 88.6%
Market Volatility: 14.0%
Analysis Details
Benchmark: SPY
Data Points: 134
Period: 252 trading days
Data Points: 134
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
COAG Institutional Ownership (13F)
Filings for 2026-06-30 · 12 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
COAG Insider Trading (Form 4)
Latest: 2026-09-25Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-25 | Keli Walbert | Director | Grant (A) | +36,000 opt | — | EDGAR | |
| 2026-06-17 | Peter Kolchinsky | 10%+ Owner | Buy (P) | +67,669 | $24.97 | $1.69M | EDGAR |
| 2026-05-21 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | Buy (P) | +4,798 | $24.96 | $119.8K | EDGAR |
| 2026-05-14 | Rajeev M. Shah | 10%+ Owner | Buy (P) | +6,387 | $24.90 | $159.0K | EDGAR |
| 2026-05-11 | RA Capital Healthcare Fund LP | 10%+ Owner | Buy (P) | +51,258 | $24.75 | $1.27M | EDGAR |
| 2026-05-06 | Novo Holdings A/S | 10%+ Owner | Conv (C) | +4,180,550 | — | EDGAR | |
| 2026-05-06 | Rajeev M. Shah | Director | Mixed Buy +2,840,429 · Conv +4,838,086 |
+7,678,515 | $18.39 | $52.22M | EDGAR |
| 2026-05-04 | Mads Nikolaj Behrndt-Eriksen | See Remarks | Grant (A) | +244,222 RSU | — | EDGAR | |
| 2026-05-04 | John Maraganore | Director | Conv (C) | +35,948 | — | EDGAR | |
| 2026-05-04 | Catherine Madigan | Chief Medical Officer | Grant (A) | +194,150 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
COAG Insider Holdings
6 insiders · @ $40.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Healthcare Fund LP | 10%+ Owner | 6,325,914 | $258.86M | $1.27M | 1 | 2026-05-11 |
| 2 | Novo Holdings A/S | 10%+ Owner | 4,180,550 | $171.07M | $0 | 1 | 2026-05-06 |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | 1,009,052 | $41.29M | $119.8K | 1 | 2026-05-21 |
| 4 | Peter Kolchinsky | 10%+ Owner | 1,009,052 | $41.29M | $1.69M | 1 | 2026-06-17 |
| 5 | Rajeev M. Shah | Director | 354,938 | $14.52M | $52.38M | 2 | 2026-05-14 |
| 6 | John Maraganore | Director | 35,948 | $1.47M | $0 | 1 | 2026-05-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
COAG Board & Officers
As of SEC filings through Sep 25, 2026Directors 7
- Akshay Vaishnaw · since Apr 30, 2026
- Benny Sorensen · since Apr 30, 2026
- John Maraganore · since Apr 30, 2026
- Linda Bain · since Apr 30, 2026
- RA Capital Nexus Fund II, L.P. (entity) · since Apr 30, 2026
- RA Capital Nexus Fund IV, L.P. (entity) · since Apr 30, 2026
- Keli Walbert · since Sep 24, 2026
Officers 4
- Mads Nikolaj Behrndt-Eriksen · Chief Financial Officer and General Manager · since Apr 30, 2026
- Ananthram Sreenivasa Murthy · Chief Operating Officer · since Apr 30, 2026
- Catherine Madigan · Chief Medical Officer · since Apr 30, 2026
- Benny Sorensen · since Apr 30, 2026
10% owners 9
- AI Biotechnology LLC (entity) · since May 4, 2026
- AI Den-Mab LLC (entity) · since May 4, 2026
- Access Industries Holdings LLC (entity) · since May 4, 2026
- Access Industries Management, LLC (entity) · since May 4, 2026
- Len Blavatnik · since May 4, 2026
- Peter Kolchinsky · since Apr 30, 2026
- RA Capital Healthcare Fund LP (entity) · listed since May 2026
- Ra Capital Management, L.p. (entity) · since Apr 30, 2026
- Rajeev M. Shah · since Apr 30, 2026
Changes in the last 10 years (32)
| Sep 24, 2026 | Keli Walbert became a director |
| May 11, 2026 | Rajeev M. Shah no longer listed as a director in SEC filings |
| May 11, 2026 | Ra Capital Management, L.p. no longer listed as a director in SEC filings |
| May 11, 2026 | RA Capital Healthcare Fund LP no longer listed as a director in SEC filings |
| May 11, 2026 | Peter Kolchinsky no longer listed as a director in SEC filings |
| May 8, 2026 | The company announced the departure of Laura Tadvalkar from the board in an SEC filing |
| May 6, 2026 | RA Capital Healthcare Fund LP first listed as a 10% owner in an SEC filing |
| May 6, 2026 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| May 4, 2026 | Len Blavatnik became a 10% owner |
| May 4, 2026 | Access Industries Management, LLC became a 10% owner |
| May 4, 2026 | Access Industries Holdings LLC became a 10% owner |
| May 4, 2026 | AI Den-Mab LLC became a 10% owner |
| May 4, 2026 | AI Biotechnology LLC became a 10% owner |
| Apr 30, 2026 | Rajeev M. Shah became a director |
| Apr 30, 2026 | Rajeev M. Shah became a 10% owner |
| Apr 30, 2026 | Ra Capital Management, L.p. became a director |
| Apr 30, 2026 | Ra Capital Management, L.p. became a 10% owner |
| Apr 30, 2026 | RA Capital Nexus Fund IV, L.P. became a director |
| Apr 30, 2026 | RA Capital Nexus Fund II, L.P. became a director |
| Apr 30, 2026 | RA Capital Healthcare Fund LP became a director |
| Apr 30, 2026 | Peter Kolchinsky became a director |
| Apr 30, 2026 | Peter Kolchinsky became a 10% owner |
| Apr 30, 2026 | Novo Holdings A/S became a 10% owner |
| Apr 30, 2026 | Mads Nikolaj Behrndt-Eriksen became Chief Financial Officer and General Manager |
| Apr 30, 2026 | Linda Bain became a director |
| Apr 30, 2026 | Laura Tadvalkar became a director |
| Apr 30, 2026 | John Maraganore became a director |
| Apr 30, 2026 | Catherine Madigan became Chief Medical Officer |
| Apr 30, 2026 | Benny Sorensen became an officer |
| Apr 30, 2026 | Benny Sorensen became a director |
| Apr 30, 2026 | Ananthram Sreenivasa Murthy became Chief Operating Officer |
| Apr 30, 2026 | Akshay Vaishnaw became a director |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-10
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
31 ETFs hold COAG
25 shown · $91.45M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.22% | $22.7M | $10.5B | 2026-11-09 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $22.0M | $77.8B | 2026-11-09 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $17.1M | — | 2026-09-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $6.2M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.03% | $4.8M | $14.1B | 2026-11-09 |
| 6 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $3.8M | — | 2026-08-31 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.5M | — | 2026-09-30 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $3.2M | $14.1B | 2026-11-09 |
| 9 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.10% | $1.6M | — | 2026-07-31 |
| 10 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.04% | $1.2M | — | 2026-06-30 |
| 11 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.1M | $95.3B | 2026-11-09 |
| 12 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.14% | $844,941 | — | 2026-11-10 |
| 13 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $656,748 | $10.4B | 2026-11-09 |
| 14 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $547,571 | — | 2026-08-31 |
| 15 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.02% | $406,224 | — | 2026-09-30 |
| 16 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $368,082 | — | 2026-11-10 |
| 17 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $338,927 | $4.1B | 2026-11-09 |
| 18 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $232,030 | $20.3B | 2026-11-09 |
| 19 | FBCG Fidelity Blue Chip Growth ETF | Nport | 0.00% | $222,439 | — | 2026-07-31 |
| 20 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $221,647 | — | 2026-09-30 |
| 21 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.02% | $112,359 | — | 2026-08-31 |
| 22 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $55,268 | $14.7B | 2026-11-09 |
| 23 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.01% | $54,069 | $672.8M | 2026-11-09 |
| 24 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $51,657 | — | 2026-09-30 |
| 25 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.02% | $42,802 | — | 2026-11-10 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
COAG vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ABBV ABBVIE INC. | $518.4B | 50.1 | +10.7% | +27.0% | 38 |
| AMGN Amgen Inc | $251.6B | 26.8 | +8.2% | +40.8% | 40 |
| GILD Gilead Sciences Inc | $210.0B | — | +6.5% | +39.5% | 49 |
| MRNA Moderna, Inc. Common Stock | $108.8B | — | −27.6% | +718.9% | 48 |
| NTRA Natera, Inc. Common Stock | $46.5B | — | +36.6% | +40.7% | 39 |
| BIIB Biogen Inc. Common Stock | $37.7B | 107.6 | +2.3% | +41.5% | 100 |
| EXEL Exelixis Inc | $17.5B | 21.0 | +9.1% | +60.9% | 45 |
| HALO Halozyme Therapeutics, Inc. | $11.7B | 29.2 | +41.2% | +42.5% | 33 |
| COAG Hemab Therapeutics Holdings, Inc. Common | $2.0B | — | — | +20.4% | — |
| Peer median | $77.7B | 29.2 | +8.6% | +41.2% | 42 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.